Social network
Our Company - Contributing with pride and passion, beyond expectations
Our Company - Contributing with pride and passion, beyond expectations

Our Company

Contributing with pride and passion, beyond expectations

Tools content (print, share, increase/decrease text size):


Middle area:

The 2012 Bio International Convention


June 20, 2012



The 2012 BIO International Convention is being held from June 18 to 21 in Boston, Massachusetts, a region which now has the highest concentration of biotechnology researchers in the United States.

The BIO International Convention, whose 2012 theme is “Connect. Partner. Innovate” brings together major players in the biotechnology sector. With more than 15,000 participants from 65 countries, BIO offers a broad range of opportunities for meetings and discussions that may lead to new partnerships. Sanofi – the event’s double helix sponsor – will be in the Mass Pavilion and participate with Sanofi Pasteur and Genzyme in a dozen sessions.

Sanofi will be represented by its CEO, Christopher A. Viehbacher, by Elias Zerhouni, President Global R&D, and by David Meeker, President and CEO of Genzyme. Christopher A. Viehbacher will speak twice during the Convention to a panel of experts on the theme of Innovation in sessions entitled "Biotech and Big Pharma - What's next?” And “Pre-competitive collaboration: Innovation of the future?”.


Interview of Christopher A. Viehbacher, CEO, with CNBC

The importance of partnerships and innovation

Today there are seven billion people in the world who sooner or later in life will require healthcare and treatment. To address public health issues and meet patients’ expectations in areas such as oncology, genetic diseases, neurodegenerative or autoimmune diseases, Sanofi is building on collaboration efforts with partners to optimize opportunities for partnerships that can lead to innovative therapeutic solutions. A total of 101 partnerships and acquisitions were carried out between 2009 and 2011 with private companies and public bodies (universities, biotech companies, research centers and pharmaceutical companies). The latest collaboration agreement was signed on June 19, 2012 with the Joslin Diabetes Center, affiliated to the Harvard Faculty, and concerns research into new drugs against diabetes. In biotechnology, since the acquisition of Genzyme, Sanofi has strengthened its footprint in rare diseases, an area where there are still a considerable number of unmet patients' needs.


© Sanofi 2004-2016 - All rights reserved - Update: March 10, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)